We provide the latest news
from the world of economics and finance
(RTTNews) - BioCryst Pharmaceuticals, Inc. (BCRX) announced the Brazilian Health Regulatory Agency has granted approval for oral, once-daily ORLADEYO for the prophylaxis of hereditary angioedema attacks in adults and pediatric patients 12 years of age or older.
BioCryst has an exclusive collaboration with Pint Pharma to register and promote ORLADEYO in the pan-Latin America region. Pint is responsible for obtaining and maintaining all marketing authorizations and for commercializing ORLADEYO in the region.
"We are excited to announce that ORLADEYO is now approved in the region's largest market, following the positive regulatory decisions we received in Chile and Argentina last year," said Charlie Gayer, chief commercial officer of BioCryst.
For More Such Health News, visit rttnews.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
© 2024 Lime Trading (CY) Ltd
Lime Trading (CY) Ltd is authorised and regulated by the Cyprus Securities and Exchange Commission in accordance with license No.281/15 issued on 25/09/2015. The "Just2Trade" trademark is owned by LimeTrading (CY) Ltd.
Registration Number: HE 341520
Address: Lime Trading (CY) Ltd
Magnum Business Center, Office 4B, Spyrou Kyprianou Avenue 78
Limassol 3076, Cyprus
Disclaimer:
All promotions, materials and information of this website may have applied conditions. Please contact the Company for further details
Trading on financial markets carries risks. The value of the investments can both increase and decrease and the investors may lose all their investment capital. In case of a leveraged product, the loss may be more than the initial capital invested. Detailed information on risks associated with trading on financial markets can be found in General Terms and Conditions for the Provision of Investment Services..